SCHEMBL6790364

SCHEMBL6790364

COC(=O)c1ccc(C(=O)Nc2cccnc2)cc1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TERT O14746 4/20 0.52
SIRT2 Q8IXJ6 1/20 0.50
RAB9A P51151 4/20 0.48
KDM4E B2RXH2 4/20 0.48
NPC1 O15118 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 2/20 0.48
GAA P10253 2/20 0.48
TSHR P16473 1/20 0.48
PKM P14618 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
ALDH1A1 P00352 3/20 0.48
HSD17B10 Q99714 1/20 0.48
LMNA P02545 1/20 0.48
NAMPT P43490 2/20 0.46
KMT2A Q03164 3/20 0.46
POLB P06746 1/20 0.46
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6787594 0.91 TERT (0.63) TERTSIRT2RAB9AKDM4ENPC1
SCHEMBL6786540 0.90 NPC1 (0.58) TERTSIRT2RAB9AKDM4ENPC1
SCHEMBL6781497 0.90 TERT (0.60) TERTRAB9AKDM4ENPC1GAA
SCHEMBL6784893 0.86 ALDH1A1 (0.51) TERTKDM4EGAATSHRALDH1A1
SCHEMBL6784370 0.84 TERT (0.62) TERTRAB9AKDM4ENPC1MAPT
SCHEMBL6785362 0.84 TERT (0.59) TERTRAB9AKDM4ENPC1GAA
SCHEMBL6782397 0.84 TERT (0.64) TERTKDM4EMAPTGAATSHR
SCHEMBL6781040 0.83 TERT (0.59) TERTRAB9AKDM4ENPC1MAPT
SCHEMBL6785460 0.82 TERT (0.60) TERTRAB9AKDM4ENPC1MAPT
SCHEMBL6787458 0.82 TERT (0.58) TERTRAB9AKDM4ENPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885SIRT2 547/4885RAB9A 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.